← Leaderboards
Karel Petrak
Agennix, Inc.
$2,545,989
Attributed
$2,545,989
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2006–09$2M$1.5M$1M$500K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$2,545,989 · 5
By mechanism
R44$1,949,665 · 2
R43$480,524 · 2
R41$115,800 · 1
Top collaborators
No co-investigators on record.
Most similar at Agennix, Inc.
Same institution · by research overlap
- Atul Varadhachary$8,122,423
- Elizabeth J Dial$1,412,539
Others in their field
Top investigators on “Lactoferrin”
- Cynthia Nau Cornelissen · Virginia Commonwealth University$6,783,279
- Jeffrey K Actor · Pharmareview Corporation$6,158,531
- Sarah F Hamm-Alvarez · University Of Southern California$3,704,136
- Daniel H Fine · Univ Of Med/Dent Of Nj-Nj Dental School$3,359,935
- Natalia Teleshova · Population Council$3,300,300
- David A Stoltz · University Of Iowa$3,215,297
Research focus
LactoferrinClinical ResearchMorbidity - Disease RateRecombinantsEnrollmentCostLaboratoriesDouble-Blind MethodMortality Vital StatisticsRandomizedSepsisSeveritiesPlacebosOralIncidenceSafetyInfectionInflammationEventEnteralFeedingDrug Design /Synthesis /ProductionCharacteristicsAdverse Event
Grant awards (6)
Treatment of Sepsis with Talactoferrin$820,614
R44 · FY2009 · GM · contact PI
Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants$571,731
R44 · FY2009 · HD · contact PI
Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants$557,320
R44 · FY2008 · HD · contact PI
Treatment of Sepsis using Recombinant Human Lactoferrin$130,595
R43 · FY2006 · GM · contact PI
Recombinant human lactoferrin to treat oral mucositis$349,929
R43 · FY2004 · DE
Recombinant Lactoferrin and Necrotizing Enterocolitis$115,800
R41 · FY2004 · HD